Riskpilot← Back to searchSign inGet full accessFFT Medical AB
ABActiveOrg 5568187214Lahällsvägen 48Research and experimental development on natural sciences and engineering · NACE 7210Est. 20100 employees
Revenue 2024
SEK 40K
+700% vs 2023
EBITDA margin
-117.0%
+47% vs 2023
Equity ratio
97.2%
Financial strength
Net profit 2024
SEK 453K
+117% vs 2023
| Revenue | SEK 40K | +700% |
| EBITDA | SEK -47K | +47% |
| Net profit | SEK 453K | +117% |
| Total assets | SEK 1,6M | +40% |
| Equity | SEK 1,6M | +41% |
| Employees | 0 | — |
Legal name
FFT Medical AB
Org number
5568187214
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
14 september 2010
Share capital
SEK 278 750
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna Registrerad kvalificerad revisor saknas.
Company purpose
Bolaget ska bedriva forskning och utveckling inom det medicinska området, marknadsföra och försälja medicinska tjänster och produkter ävensom idka annan därmed förenlig verksamhet.
Address
Lahällsvägen 48
Phone
+4686226700
Email
info@fftmedical.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 339 | 0 | 100 | 5 | 40 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 174 | −69 | −140 | −89 | −47 |
| Depreciation & amort. | −56 | −58 | −58 | −0 | — |
| EBIT | 118 | −127 | −198 | −89 | −47 |
| Net financials | — | — | 1 000 | −4 039 | 500 |
| Profit before tax | 118 | −127 | 802 | −2 628 | — |
| Tax | −0 | −0 | −0 | −0 | — |
| Net profit | 118 | −127 | 802 | −2 628 | 453 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 3 114 | 2 971 | 3 774 | 1 144 | 1 599 |
| Equity | 3 054 | 2 926 | 3 729 | 1 101 | 1 554 |
| Long-term debt | 0 | 0 | 0 | 0 | — |
| Short-term debt | 60 | 45 | 45 | 43 | 45 |
| Total debt | 60 | 45 | 45 | 43 | 45 |
EBITDA margin
-117.0%
This company
15.8%
Market median
-841% vs market
20202024
Equity ratio
97.2%
This company
38.2%
Market median
+154% vs market
20202024
Return on equity
29.2%
This company
18.4%
Market median
+59% vs market
20202024
Net profit margin
1133.1%
This company
8.1%
Market median
+13889% vs market
20202024
Asset turnover
0.03×
This company
1.12×
Market median
-97% vs market
20202024
Debt / equity
0.03×
This company
0.62×
Market median
+95% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
LG Chief Executive Officer | Chief Executive Officer | 2022 |
LE | Audit | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
FFT Medical AB 
Nutrinovate ABBoard members of FFT Medical AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars Gunnar Johan Byström | Chief Executive Officer | 0 companies |
| Lars Erik Ingemar Lidgren | Audit | 0 companies |
| Thomas Johan Ekerborn | Chairman | 0 companies |
| Claes Fredrik Hübinette | Deputy Board Member | 0 companies |